Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 7/2014

01.07.2014 | Hypertension and the Heart (SD Solomon and O Vardeny, Section Editors)

Hypertension as a Risk Factor for Heart Failure

verfasst von: Arun Kannan, Rajesh Janardhanan

Erschienen in: Current Hypertension Reports | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Hypertension remains a significant risk factor for development of congestive heart failure CHF), with various mechanisms contributing to both systolic and diastolic dysfunction. The pathogenesis of myocardial changes includes structural remodeling, left ventricular hypertrophy, and fibrosis. Activation of the sympathetic nervous system and renin-angiotensin system is a key contributing factor of hypertension, and thus interventions that antagonize these systems promote regression of hypertrophy and heart failure. Control of blood pressure is of paramount importance in improving the prognosis of patients with heart failure.
Literatur
1.••
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245. Hypertensive heart disease remains the major risk factor for various medical conditions.PubMedCrossRef
2.
Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 Suppl A):6A–13A.PubMedCrossRef
3.
Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.PubMedCrossRef
4.
Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 1996;156(16):1789–96.PubMedCrossRef
5.
Perry Jr HM, Bingham S, Horney A, Rutan G, Sambhi M, Carmody S, et al. Antihypertensive efficacy of treatment regimens used in Veterans Administration hypertension clinics. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Hypertension. 1998;31(3):771–9.PubMedCrossRef
6.
Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic heart failure. Adv Cardiol. 1986;34:124–30.PubMed
7.
Frohlich ED. An updated concept for left ventricular hypertrophy risk in hypertension. Ochsner J. 2009;9(4):181–90.PubMedCentralPubMed
8.•
Raman SV. The hypertensive heart. An integrated understanding informed by imaging. J Am Coll Cardiol. 2010;55(2):91–6. Recognition of hypertensive disease has prognostic implications.PubMedCentralPubMedCrossRef
9.
Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol. 2005;289(1):H8–H16.PubMedCrossRef
10.
Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001;38(7):1829–35.PubMedCrossRef
11.
Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25(4):879–84.PubMedCrossRef
12.
Tomanek RJ, Wessel TJ, Harrison DG. Capillary growth and geometry during long-term hypertension and myocardial hypertrophy in dogs. Am J Physiol. 1991;261(4 Pt 2):H1011–8.PubMed
13.
Lorell BH, Grossman W. Diastolic relaxation of the heart: the biology of diastole in health and disease. 2nd ed. Boston: Kluwer Academic Publishers; 1994. xiii, 348 p. p.CrossRef
14.
Grimson KS. Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension. Ann Surg. 1941;114(4):753–75.PubMedCentralPubMedCrossRef
15.•
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. Catheter-based renal denervation causes substantial and sustained blood-pressure reduction in patients with resistant hypertension.PubMedCrossRef
16.•
Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976–82. Renal denervation provides sustained drop in blood pressure in patients with resistant hypertension.PubMedCrossRef
17.
Esler M. In: Birkenhäger WH, editor. Handbook of hypertension. 25.
18.•
Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33(9):1058–66.PubMedCrossRef
19.
Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73(4):615–21.PubMedCrossRef
20.
Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311(13):819–23.PubMedCrossRef
21.
Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26(5):1257–63.PubMedCrossRef
22.
Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66(4):883–90.PubMedCrossRef
23.
Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol. 1990;66(11):22D–30D. discussion D-2D.PubMedCrossRef
24.
Harrap SB, Dominiczak AF, Fraser R, Lever AF, Morton JJ, Foy CJ, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation. 1996;93(6):1148–54.PubMedCrossRef
25.
Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41–6.PubMedCrossRef
26.
Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996;275(19):1507–13.PubMedCrossRef
27.
Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation. 1997;96(4):1173–9.PubMedCrossRef
28.
Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, et al. Endothelin in human congestive heart failure. Circulation. 1994;89(4):1580–6.PubMedCrossRef
29.
Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol. 1993;71(7):602–4.PubMedCrossRef
30.
Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension. N Engl J Med. 1992;327(14):998–1008.PubMedCrossRef
31.
Rame JE, Ramilo M, Spencer N, Blewett C, Mehta SK, Dries DL, et al. Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. Am J Cardiol. 2004;93(2):234–7.PubMedCrossRef
32.•
Milani RV, Drazner MH, Lavie CJ, Morin DP, Ventura HO. Progression from concentric left ventricular hypertrophy and normal ejection fraction to left ventricular dysfunction. Am J Cardiol. 2011;108(7):992–6. Approximately 13% of patients with concentric LV hypertrophy and normal ejection fraction progress to systolic dysfunction when followed up for three years. PubMedCrossRef
33.•
Krishnamoorthy A, Brown T, Ayers CR, Gupta S, Rame JE, Patel PC, et al. Progression from normal to reduced left ventricular ejection fraction in patients with concentric left ventricular hypertrophy after long-term follow-up. Am J Cardiol. 2011;108(7):997–1001. In patients with concentric left ventricular hypertrophy, the progression of LVH from a normal LVEF to a low LVEF is infrequent (20%) during a long-term follow-up study.PubMedCrossRef
34.
Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43(12):2207–15.PubMedCrossRef
35.•
Janardhanan R, Desai AS, Solomon SD. Therapeutic approaches to diastolic dysfunction. Curr Hypertens Rep. 2009;11(4):283–91. Abnormalities of passive stiffness or active relaxation of the myocardium impair ventricular filling during diastole and may contribute to the development heart failure with preserved ejection fraction.PubMedCrossRef
36.
Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. Cardiovasc Res. 2000;45(4):813–25.PubMedCrossRef
37.
Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001;104(7):779–82.PubMedCrossRef
38.
Zile MR. Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol. 2003;41(9):1519–22.PubMedCrossRef
39.
Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111(6):774–81.PubMedCrossRef
40.
Phillips RA, Goldman ME, Ardeljan M, Arora R, Eison HB, Yu BY, et al. Determinants of abnormal left ventricular filling in early hypertension. J Am Coll Cardiol. 1989;14(4):979–85.PubMedCrossRef
41.
Eberli FR, Apstein CS, Ngoy S, Lorell BH. Exacerbation of left ventricular ischemic diastolic dysfunction by pressure-overload hypertrophy. Modification by specific inhibition of cardiac angiotensin converting enzyme. Circ Res. 1992;70(5):931–43.PubMedCrossRef
42.
Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension. 1996;28(2):269–75.PubMedCrossRef
43.
Smith WM. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res. 1977;40(5 Suppl 1):I98–I105.PubMed
44.
Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281–5.PubMedCrossRef
45.
Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5(5):561–72.PubMedCrossRef
46.
Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90(4):1786–93.PubMedCrossRef
47.
Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21(5):500–8.PubMedCrossRef
48.
Borhani NO, Blaufox MD, Oberman A, Polk BF. Incidence of coronary heart disease and left ventricular hypertrophy in the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis. 1986;29(3 Suppl 1):55–62.PubMedCrossRef
49.
Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5(2):95–110.PubMed
50.
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003;108(6):684–90.PubMedCrossRef
51.
Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 2001;104(11):1248–54.PubMedCrossRef
52.
Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831–8.PubMedCrossRef
53.
de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994;23(6):1444–51.PubMedCrossRef
54.
Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2001;37(4):1042–8.PubMedCrossRef
55.
Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, et al. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation. 2002;106(2):227–32.PubMedCrossRef
56.••
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292(19):2343–9. Antihypertensive therapy result in regression of electrocardiographic LVH and may improve prognosis.PubMedCrossRef
57.
Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97(1):48–54.PubMedCrossRef
58.
Pierdomenico SD, Lapenna D, Cuccurullo F. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens. 2008;21(4):464–70.PubMedCrossRef
59.
Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24(11):2163–8.PubMedCrossRef
60.
Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press. 1998;7(3):176–83.PubMedCrossRef
61.
Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296(10):1242–8.PubMedCrossRef
62.•
Rials SJ, Wu Y, Xu X, Filart RA, Marinchak RA, Kowey PR. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation. 1997;96(4):1330–6. Regression of LVH with captopril normalizes the electrophysiological abnormalities of ventricular hypertrophy and reduces the vulnerability to ventricular fibrillation.PubMedCrossRef
63.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991 Aug 1;325(5):293–302.
64.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987 Jun 4;316(23):1429–35.
65.
Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41(9):1529–38.PubMedCrossRef
66.
Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 2002;40(2):311–7.PubMedCrossRef
67.•
Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012;4, CD003040. Adding an angiotensin receptor blocker in combination with an angiotensin-converting enzyme inhibitor does not reduce total mortality or total hospital admissions, but does increase withdrawals due to adverse effects, compared with angiotensin-converting enzyme inhibitors alone.PubMed
68.
Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103(1):72–7.PubMedCrossRef
69.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.PubMedCrossRef
70.
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.PubMedCrossRef
71.
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349–55.PubMedCrossRef
72.
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.PubMedCrossRef
73.
Investigation G. Digitalis. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.CrossRef
Metadaten
Titel
Hypertension as a Risk Factor for Heart Failure
verfasst von
Arun Kannan
Rajesh Janardhanan
Publikationsdatum
01.07.2014
Verlag
Springer US
Erschienen in
Current Hypertension Reports / Ausgabe 7/2014
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-014-0447-7

Weitere Artikel der Ausgabe 7/2014

Current Hypertension Reports 7/2014 Zur Ausgabe

Secondary Hypertension: Nervous System Mechanisms (J Bisognano, Section Editor)

Diagnosis and Management of Pheochromocytoma: A Practical Guide to Clinicians

Hypertensive Emergencies (BM Baumann, Section Editor)

Current and Newer Agents for Hypertensive Emergencies

Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

Individualizing Antihypertensive Combination Therapies: Clinical and Hemodynamic Considerations

Hypertension and the Kidney (R Carey, Section Editor)

AT2 Receptors Targeting Cardiac Protection Post-Myocardial Infarction

Hypertension and the Kidney (R Carey, Section Editor)

The Protective Arms of the Renin-Angiontensin System in Stroke

Hypertension and the Kidney (R Carey, Section Editor)

ACE Overexpression in Myelomonocytic Cells: Effect on a Mouse Model of Alzheimer’s Disease

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise